The Russian Diabetes Federation estimates that by 2025 more than 10 million Russians will suffer from diabetes. In 2007 there were an estimated 7.8 million diabetics.
Danish pharmaceuticals group Novo Nordisk (NOVOb.CO) sees big growth prospects for insulin in the Russian market, comparable to its experience in China.
Novo Nordisk expects “growth rates in Russia of over 20 percent for a number of years into the future…”
Link to the article:
Rather than looking so far into the future, Novo’s CEO Lars Sorensen might want to take a lateral look at the present. He might want to look at those industries that have recently been classified as a “strategic country asset” in Russia.
As noted earlier, we raised the specter of pharmaceutical nationalization in Russia in the November 2008 issue of the PHM Emerging Markets Healthcare Monitor. Not a country to shy away from a provincial esprit, Russia can certainly take France’s position on healthcare in the EU. (See Miscellaneous Watch in this issue.) That is, keep it in the country for the good of the system.
But more than that, what with Russia’s increased budget for healthcare expenditures coupled with the political use of nationalism that is fermenting around the world, (see page 11 AON’s political risk map.) we hear there’s a growing lack of confidence in corporate ownership in Russia for the time being…..HK